Taxane-Based Neoadjuvant Chemotherapy

Phase 2Small molecule

Taxane-Based Neoadjuvant Chemotherapy is one of 35 small molecule programs targeting Breast Cancer. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Breast CancerActive, not recruiting

Hormone-Receptor-Positive Breast CancerRecruiting

Breast CancerPhase 2

Active, not recruiting

Hormone-Receptor-Positive Breast CancerPhase 2

Recruiting

Competition

Competitive Landscape

2828 competitors in Breast Cancer

#DrugCompanyPhaseTrials

Tecentriq

Roche

Preclinical

36 2

Adriamycin

GGynecologic Oncology Group

Preclinical

87 3

Gemzar

GGynecologic Oncology Group

Preclinical

22 4

Adenocard

Astellas

Preclinical

1 5

Zolymbus

AbbVie

Preclinical

1 6

Lexiscan

Astellas

Preclinical

1 7

Taxane-Based Neoadjuvant Chemotherapy

PPeking University People's Hospital

Phase 2

1 8

Chantix

PPrism Pharmaceuticals

Preclinical

1 9

Acupan

YYonsei University

Preclinical

1 10

Vfend

PPrism Pharmaceuticals

Preclinical

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2029

Phase 2Recruiting

Hormone-Receptor-Positive Breast Cancer

NCT06970912

Clinical

Trials by Indication[1]

Hormone-receptor-positive Breast Cancer1 trial

A Prospective, Multicenter, Randomized, Open-Label Phase II Study of ctDNA-Guided De-Escalation of Adjuvant Chemotherapy With Dalpiciclib in HR-Positive/HER2-Negative Breast Cancer

Recruiting·PPeking University People's Hospital·Phase 2·NCT06970912·393 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Taxane-Based Neoadjuvant Chemotherapy. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Taxane-Based Neoadjuvant Chemotherapy compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Taxane-Based Neoadjuvant Chemotherapy. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Peking University People's Hospital company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: PPeking University People's Hospital

Taxane-Based Neoadjuvant Chemotherapy

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2029

Trials by Indication[1]

Hormone-receptor-positive Breast Cancer1 trial

References

Drug Info

Quick Facts

Related News